Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Biotage, Audiocast, Q1'25

By Inderes4/23/2025, 7:00 AM
Biotage

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Frederic Vanderhaegen
00:00 - 03:05

Thank you. Good morning, everyone. Welcome to our Q1 report. Thank you for your flexibility today and for accommodating our recent time changes. Today's call is about the Q1 release. We will not comment on the recent announcements made by KKR. We would encourage anyone who has a question to reach out to Torben Jorgensen, who is our chairman of a subcommittee. That will address your questions going forward. Let me talk about our Q1 results. As expected, our Q1 revenue was softer than the prior year, primarily due to the volatility within our bioprocessing, which we had previously commented upon. Our relatively large exposure to the Plasmid preparation business has impacted our overall performance. However, we did see growth in our plasmid preparation revenue and bioprocessing. Gross margin continued to expand sequentially to reach 73.5%. We continue to build a strong foundation for future bioprocessing successes. Expanding our customer base. In this quarter, we added 37 new customers in the early phase of drug discovery, and over the past two years, we added more than 220 new customers. Our sales pipeline is strengthening, and we focus on partnering with our customers as they progress their modalities into late-stage development, which is going to be key as a leading indicator for future growth in the quarter. We took decisive actions to rightsize our bioprocessing cost base and drive strong integration, with the benefit of this starting to flow from quarter two onwards. This has been driven by a slowdown in our analytical testing activities, primarily due to a rationalization in one of our customer's operations and also some delay in purchasing decisions for systems coming mostly from the US. As a consequence of macroeconomic factors and recent announcements made by the Board. We were encouraged by the rebound in demand within the drug discovery segments, particularly in the North American area. We also saw growth in the Asia Pacific region, with China reporting quarter over quarter growth. Now, our demand continues to outstrip manufacturing capacity when it comes to our peptides. Had we been able to supply the peptide backlog, we would have been able to report mid-single digit growth in revenue for the core business. Our gross margin in the core business grew sequentially quarter over quarter and as regional, at 61.7%. Although we do recognize that the Q1 results are disappointing, we ourselves are not satisfied with them. We were pleased that March saw improvement momentum with mid-single-digit growth in consumable orders, which is very promising for onward revenue. We remain confident in our future mid to long-term outlook while managing the short-term headwinds with the right-sized cost base. Let me now turn it over to Andrew, who's going to walk you through more details on our financials. Thank you.

Andrew Kellett
03:06 - 09:22

Thank you, Fred. Good morning, everybody. The Q1 report, along with the presentation that's on the screen now, is available on the Biotage website under the investor section. And then financial reports. So in Q1, as Fred has just commented, our revenues were softer than Q1 2024, primarily due to the volatility within bioprocessing or large molecules, as we've previously flagged. Astrea has only a small number of customers who have products in the commercial stage, i.e., Released in the market. Fluctuations in demand from these customers can and do have a material impact on its revenue on a quarterly basis. Therefore, it has been repeatedly said that you cannot judge bioprocessing performance on a quarterly basis. As our business grows and matures, we see more of our early-stage customers' modalities moving into late-stage development and into production and commercialization. Our revenue concentration will ease and with it, our overall volatility. However, this is not measured in quarters, but rather in years. While we cannot say when and how fast those modalities will move through the pipeline, we are confident that the actions we are taking now will deliver the best chances of future success. Now our large molecules bioprocessing revenues were significantly down in Q1, as you've seen, due to lower plasmid preparation revenue in Q1 2025. We did not have any plasma revenue compared to approximately 90 million in Q1 2024. However, our Plasmid preparation revenue grew by 3% compared to Q1 2024. We did see growth of 3% in our small molecules revenue. Additionally, we saw growth in China of 16% in the quarter after a few years of consistent heavy declines, as we've noted in the Q1 report. We continued to see robust demand for our peptide systems, with demand outpacing manufacturing capacity, which has improved year on year. We experienced challenges in our analytical testing segment, with revenues declining by 8% year on year. This was driven by both specific macro factors and the rationalization of one of our customer's operations. We acquired 37 new customers in Q1. In early-stage research, we are adopting a much more rigorous approach to pipeline management, classifying our customers by clinical stage to give us better visibility of future revenue streams. Although we cannot predict when and if a customer will progress through the pipeline, the more customers we acquire and the more we partner with them in solving their problems, we increase our chances of future success. This, as Fred has always commented, is a numbers game requiring a medium-term outlook. While we are on this journey, we can still expect some significant short-term revenue volatility. As Fred has commented, our gross margins in the quarter were actually very strong on a group level. They were just under 63%, broadly on par with a very strong comparable Q1 2024 and up 1.1% sequentially on Q1, Q4 24. In bioprocessing, our Astrea business Q1 margins were 73.5%, up 7.87 points compared to Q1 2024 and 2.3 points sequentially. In the core quarter, one margins were 61.7%, up 5.1 points sequentially and just a small decline from a very strong comparable Q1 2024. Total operating costs in Q1 were $254 million, compared to $236 million in Q1 2024. However, when you adjust for one-off non-recurring costs, which were 22 million in Q1 versus 14 million in Q1 24, and the impact of effect translation costs, which we took an 8 million charge in Q1 versus a 5 million credit in Q1 2024. They were much higher in Q1 2025 due to significant swings in the FX rates in March, mainly centered around the US dollar. Then our adjusted OpEx at 224 million was actually lower than Q1 2024 of 227 million. So in Q1, we delivered an adjusted EBITDA of 50 million. This was weighed down by the softness in the bioprocessing revenue to mitigate this. We have taken decisive action to streamline our bioprocessing cost base and drive further integration. The benefits of this will start to flow from Q2 this year. In the quarter, we delivered adjusted cash flow from operations of 76 million, again down on the comparable quarter due to revenue softness. However, we continue to deliver adjusted cash flow from operations ahead of adjusted EBITDA. We finished the quarter with gross cash of 434 million and net cash of 182 million, on par with December 2024. To conclude, like Fredric said, we recognize that this quarter's results are disappointing, none more so than to us. However, we are very focused on putting in the building blocks for future growth. Undoubtedly, we're facing challenging headwinds, which will make 2025 quite a volatile year. But we remain confident that the actions we're executing now will put us in a good position for future success. Recognizing the executional as well as the market risks that lie ahead of us, we're now open to take any questions.

Operator
09:25 - 09:45

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Matthias Hegbloom from Handelsbanken. Please go ahead.

Unknown 1
09:48 - 10:11

Good morning. Thanks so much for taking my question. I have. First, a clarification. So, um, you stated in the report that if you had been able to deliver at the demand for Peptide Systems, it would have translated into mid-single digit growth. It's not clear to me if that was for the Biotage group or only for Biotage. If it references the group, it's a delta. Yeah, please.

Andrew Kellett
10:11 - 10:14

It's. No, it's for the core business.

Unknown 1
10:16 - 10:33

Okay. And I'm not sure I saw that in the report, but could you remind me what the organic growth for core was? So we can back out and understand the magnitude? Or if you can help me, then. In absolute terms, how large would the backlog be, which I guess is what we're trying to determine here.

Andrew Kellett
10:34 - 10:45

Well, if you think about it, we kind of consider the backlog to be just under approximately 20 million SEK for peptide systems.

Unknown 1
10:46 - 10:58

Yep. That's helpful. And, um, remind me, what alternatives do customers have when you can't deliver? And secondly, tied to that, when do you expect to be able to produce to meet demand?

Frederic Vanderhaegen
11:00 - 11:57

Yes. So yes, we are working with the third-party providers. So I think there are two impacts. First, we can't recognize revenue. Obviously. The second one is our lead time is substantial relative to the demand. So, uh, if we look into the second part, we are clearly recognizing that we're missing opportunities in the market. Uh, since customers are looking to expand their peptide purification. So, uh, our mitigation plan has been to work with our third-party providers to unleash the potential from access to the parts. That is the first step, and we are working with them to resume the output that we had last year in Q3 and Q4. But that's the maximum we can get to. So, I think we have to look for alternative paths to accelerate our market reach there, which we're exploring right now.

Unknown 1
12:00 - 12:26

That's helpful. Two more questions, please. So on slide seven with customer numbers for Astrea, it's a nice contribution to help the outside world understand the nature of your business. Unfortunately, that may be the only time we'll get to see it as well. But I wanted to understand the math here better. New customers? Is that a net number of won and lost during the year, or has that actually not lost a single customer since 2022?

Andrew Kellett
12:28 - 12:45

Um, it is a net number. But effectively, we're not losing customers. You know, the number of lost customers. I can't think of any really off the top of my head. So effectively, those are the new customers. We're winning. The level of losses is negligible.

Unknown 1
12:48 - 13:08

That's clear. And my final point is still on slide seven. Great. With the breakdown of customers per stage, but only referencing the commercial stage and more or less all columns and fiber in the preclinical stage. Can you help me understand the revenue split between reference columns and fiber? The vast majority of revenues come from reference, then. Or how should we think about that breakdown?

Andrew Kellett
13:10 - 13:38

So, in that, the majority of you can broadly think about fiber, which obviously is a new technology. The revenue from that is very small, almost negligible from an Astrea perspective. Um, and you can think of the resin column split broadly as about 85 to 90% in resins and 10 to 15% in columns.

Unknown 1
13:40 - 13:43

Very helpful. Thanks so much. Thank you.

Operator
13:51 - 14:19

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Frederic Vanderhaegen
14:20 - 15:35

So thank you. Uh, operator. So thank you to those of you who have joined this call. So we, uh, we again, want to reiterate that we are not commenting on the announcements, and we want to encourage any of you who have questions about that topic to reach out to, uh, Torben Jorgensen, who is acting as a representative of the board, or to reach out to KKR. So, as we said, we recognize that Q1 was a challenging quarter for us, mostly driven by the situation that we had in our bioprocessing space. We entered the year with a very weak backlog, but we are committed and working on expanding our customer base and addressing the opportunities, bridging the short-term revenue gap with our packing column strategies out of our Canton site that is now commissioned and operational, which will help us accelerate our momentum onwards. And in the meantime, we continue driving our drug discovery process as well as our applied market. As an organization, we have built new strategic vectors to proceed forward, and we'll be happy to share those with you as we progress onwards on the journey. Thank you all for joining us today and we look forward to speaking to you next quarter.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…